Frontlight ResearchEarly access
CompletedPhase 2
Colchicine for the Prevention of Vascular Events After an Acute Intracerebral Hemorrhage
Key facts
- Who runs it
- Population Health Research Institute
- Where
- Canada11 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 100 people enrolled
- Started
- 4 Aug 2022
- Ended
- 3 Dec 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Colchicine Pill
- Placebo
- Record updated
- 1 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Adult participants are eligible to be included in the study only if all of the following criteria apply:
- Type of Participant and Disease Characteristics
- Participants with documented spontaneous intraparenchymal hemorrhage within 48 hours of symptom onset (or last seen normal) and
- Qualifying for at least one of the following categories:; history of symptomatic coronary, peripheral and/or carotid artery disease (severe atherosclerotic vascular disease), or ii. visualized extracranial cervical/intracranial atherosclerotic disease causing any degree of stenosis/occlusion or presence of aortic arch plaque with maximum thickness ≥1 mm (moderate atherosclerotic vascular disease), or iii. two or more risk factors including: age 60 years or older, hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease (eGFR: 15-50mL/min), history of ischemic stroke or current smoking (mild atherosclerotic vascular disease); Informed Consent
- Capable of giving signed informed consent either independently, or by a legally authorized representative (LAR), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
Who cannot take part
- Concurrent treatment with strong CYP3A4 inhibitors (atazanavir, clarithromycin, darunavir/ritonavir, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir/ritonavir) or P-gp inhibitors (cyclosporine, ranolazine)
- Medical Conditions
- Secondary causes of ICH (relating to trauma, macrovascular anomalies, neoplasms or bleeding diathesis)
- Inflammatory bowel disease or chronic diarrhea
- Known allergy or sensitivity to colchicine
- Renal insufficiency (eGFR <15mL/min); Prior/Concomitant Therapy
- Participants are excluded from the study if any of the following criteria apply:
- Cirrhosis or severe hepatic dysfunction
- Strong indication for colchicine where assignment to placebo is deemed unacceptable; Other Exclusions
- Pregnant or breast-feeding
- Inability to adhere to study procedures
- Estimated life expectancy less than 6 months at the time of enrollment
- Close affiliation with the investigational site; e.g. a close relative of the investigator, dependent person (e.g., employee or student of the investigational site)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The overall goal is to establish the safety and efficacy of colchicine in ICH patients for the prevention of major cardiovascular events and brain injury. Colchicine for the prevention of vascular events after an acute intracerebral hemorrhage (CoVasc-ICH) is a vanguard pilot trial designed to obtain the factual feasibility prerequisites essential for the planning, design, funding and execution of a subsequent phase III trial.
The 2 groups in the trial
- Oral Colchicine, 0.5mg once dailyTreatment being tested
Active colchicine tablet
Treatment: Colchicine Pill
- Oral matching placebo, once dailyPlacebo, for comparison
Matching placebo tablet
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Vanguard, Double-blind, Randomized, Placebo-controlled, Phase 2 Pilot Study to Investigate Prevention of Cardiovascular Events With Oral Colchicine 0.5mg Once Daily Compared With Placebo in Participants With Spontaneous ICH and Established, or Risk Factors for, Atherosclerosis
- Publications
- Record updated
- 1 September 2026